Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung

BACKGROUND: Different therapy regimens in non-small-cell lung cancer (NSCLC) are of rising clinical importance, and therefore a clear-cut subdifferentiation is mandatory. The common immunohistochemical markers available today are well applicable for subdifferentiation, but a fraction of indistinct c...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, H, Marwitz, S, Baron-Lühr, B, Zissel, G, Kugler, C, Rabe, K F, Zabel, P, Vollmer, E, Gerdes, J, Goldmann, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188931/
https://www.ncbi.nlm.nih.gov/pubmed/21811254
http://dx.doi.org/10.1038/bjc.2011.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188931/
https://www.ncbi.nlm.nih.gov/pubmed/21811254
http://dx.doi.org/10.1038/bjc.2011.281

Ejemplares similares